# Strategic Feedback — Grok-4.1-Fast

**Role:** Journal editor (AER perspective)
**Model:** x-ai/grok-4.1-fast
**Timestamp:** 2026-03-05T17:37:02.787409
**Route:** OpenRouter + LaTeX
**Tokens:** 15678 in / 2203 out
**Response SHA256:** e24c5d3d2341e5c5

---

## 1. THE ELEVATOR PITCH (Most Important)

This paper examines whether state Right-to-Try laws, which let terminally ill patients access experimental drugs outside clinical trials, disrupted U.S. pharma innovation markets by diverting patients and trial sites—as the industry loudly warned. Using comprehensive ClinicalTrials.gov data and staggered DiD, it finds precisely estimated null effects on trial sites, enrollment, and even terminal-illness trials. Busy economists should care because it reveals how "symbolic" policies can spark fierce debates and industry opposition without moving real-world markets, with lessons for regulatory design in high-stakes sectors like pharma.

The paper articulates this pitch reasonably well in the first two paragraphs, setting up the policy drama and industry fears before posing the question. However, it buries the null preview until para 4; the first two should lead harder with the punchline to hook readers immediately. Here's the pitch the paper should have:

> On May 30, 2018, President Trump signed the federal Right-to-Try Act amid pharma industry warnings that state versions of the law—already passed in 38 states—would gut clinical trials by letting dying patients bypass them for experimental drugs. This paper finds those fears were wrong: using the universe of 75,000+ ClinicalTrials.gov trials, we estimate null effects on trial sites (-0.4%), enrollment (-6%, insignificant), and terminal-illness trials (if anything, +7%). Right-to-Try exemplifies how symbolic legislation dominates headlines and policy fights but leaves markets untouched.

## 2. CONTRIBUTION CLARITY

The paper's contribution is the first causal evidence that Right-to-Try laws had no effect on clinical trial activity, ruling out the industry-predicted disruptions that nearly killed the federal bill.

- It differentiates itself reasonably from the 3-4 closest papers (e.g., no overlap with FDA timeline studies like Budish et al. 2015 or trial geography like Thiers et al. 2008, which are descriptive; legal/bioethics work like Darrow 2018 or Frank 2019 notes low take-up but ignores market effects). However, differentiation is mostly "first to use data here," not deeply comparative.
- Framed mostly as filling a literature gap (three paras at end of intro), but stronger on world question (policy fears vs. reality).
- A smart economist could explain it as "clean null on pharma's scare story about patient access laws hurting trials," not just "another DiD on policy X."
- To make bigger: Frame outcome as pharma *innovation* (e.g., link null sites/enrollment to no change in drug approval rates or R&D spend, via FDA data); probe mechanisms deeper (e.g., did sponsors' *expectations* shift site choices pre-law?); or compare to a "binding" access policy like Expanded Access expansions.

## 3. LITERATURE POSITIONING

This paper sits at the intersection of health economics/pharma regulation (debating trial incentives) and political economy (symbolic vs. real policy effects).

- Closest neighbors: (1) Budish, Roin, & Williams (2015, QJE) on FDA incentives slowing trials; (2) Acemoglu & Linn (2004, QJE) on regulation's innovation effects; (3) Frank (2019) on Right-to-Try take-up; (4) Edelman (1964) or Mayhew (1974) on symbolic politics (cited but econ-light); (5) Harasztosi & Lindner (2019, AER) on low-compliance wage laws' effects.
- Position as *building on and falsifying* pharma reg lit (industry fears like PhRMA's mirror FDA slowdown claims, but null here); *synthesizing* with symbolic politics (unlike gun laws with noncompliance spillovers, this is pure signaling with zero take-up).
- Currently positioned narrowly (pharma policy wonks + Right-to-Try niche), risking small audience.
- Unaware of: Broader econ on "voice without bite" policies, e.g., Luttmer & Singhal (2014, AER) on symbolic tax rhetoric; or pharma expectation channels like Hershkowitz et al. (2023, recent trial design papers). Should speak to public economics (regulatory capture? pharma lobbying as bluff?).
- Right conversation? Yes, but elevate by connecting to unexpected lit: industrial organization (voluntary opt-out neutralizes policy, like firm avoidance of mandates) or behavioral (why did sophisticated pharma overpredict disruption?).

## 4. NARRATIVE ARC

- Setup: Clinical trials are pharma's bottleneck; Right-to-Try promised patient access but pharma warned of enrollment/site collapse.
- Tension: Industry/PhRMA/bioethicists predicted diversion/avoidance/uncertainty killing trials; low take-up suggested symbolic dud.
- Resolution: Null across sites/enrollment/terminal trials; rules out 7%+ disruption.
- Implications: Symbolic laws shape debates (nearly sank federal bill) without market bite; trial system resilient to weak access rules; caution for bolder policies.

Strong arc overall—intro builds tension well, results resolve cleanly, discussion unpacks "so what." Not a "collection of results"; the story drives everything (fears unfounded due to voluntary design).

## 5. THE "SO WHAT?" TEST

- Lead with: "Pharma screamed that Right-to-Try would kill clinical trials—wrong, zero effect despite perfect data and power to spot 7% drops."
- People would lean in: Nulls are rare gold in policy DiD world; punches pharma lobbyists; timely for access debates (e.g., post-COVID trial reforms).
- Follow-up: "But did it *speed up* approvals or help patients indirectly?" (Paper nods to low take-up but doesn't pursue.)

The null itself is interesting—powers out the exact disruption story from policy fights—but paper sells it as "expected given design," slightly underplaying the value of empirical falsification (industry wasn't just wrong; their channel was DOA).

## 6. STRUCTURAL SUGGESTIONS

- Shorten Institutional Background (sec 2) by 50%—merge take-up/mechanisms into intro; move pipeline details to appendix.
- Front-load more: Move main table/fig (event study) to intro end; bury TWFE/raw trends deeper.
- No results buried in robustness—all key nulls (placebos, MDE) are main text.
- Conclusion adds zilch beyond summary/discussion redux—eliminate or make 3 sentences on policy (e.g., "Test for compelled access next").

## 7. WHAT WOULD MAKE THIS AN AER PAPER?

Honest gap: Mostly framing/ambition. Science is solid (universe data, modern DiD, powered null), but feels like a very good JHE or HE or JPubE paper—competent policy evaluation in niche (Right-to-Try), safe null without huge ambition. Novelty is real (first market test), scope ok (sites/enrollment), but lacks AER "whoa" moment: doesn't reframe pharma innovation/policy design debates or link to big lit (e.g., "this falsifies capture models where industry perfectly predicts regs"). Not novelty problem—question's fresh—but needs bolder "world" hook over lit gaps.

Single most impactful advice: Reframe entire intro/conclusion around "symbolic legislation as market-neutral signaling," positioning as first econ test of expressive policy's indirect effects (cite Mayhew/Edelman more centrally; contrast with binding symbolic cases like min wage); drop niche Right-to-Try details for broader pharma access lit synthesis—this elevates from policy note to theory-testing contribution.

### Strategic Assessment

- **Current framing quality:** Compelling
- **Contribution clarity:** Crystal clear
- **Literature positioning:** Well-positioned
- **Narrative arc:** Strong
- **AER distance:** Medium
- **Single biggest improvement:** Reframe as econ test of symbolic legislation's market effects via pharma expectations, synthesizing pol econ and IO lits for broader appeal.